Connect with us

JAMMU & KASHMIR

DAK skeptical of Russian COVID-19 vaccine | KNO

Published

on

kno news

Srinagar, Aug 12 (KNO): While Russia has approved the world’s first COVID-19 vaccine for public use, Doctors Association Kashmir (DAK) on Wednesday said they are skeptical about the claim as the vaccine has been granted license for civilian use even before the clinical trials are completed. “Mass vaccination with an incompletely tested vaccine is unethical,” said DAK President and influenza expert Dr Nisar ul Hassan in a statement issued to the news agency—Kashmir News Observer (KNO). “Russia has conducted just two trials of the vaccine with the third clinical trial yet to start,” he said. “The normal approval process of a new vaccine is to gather data from phase 1 and phase 2 clinical trials and then expand the pool of study participants in phase 3 to create enough evidence that the vaccine is effective and safe. Dr Nisar said to fully assess the efficacy and safety of a vaccine phase 3 trials are required. “The phase 3 trial is the pivotal study on which the decision on whether to grant the license is based,” he said. He said Russia has not made data from the earlier trials public and the data has not been peer-reviewed which is important for regulatory approval. “Lack of published data on vaccine - including how it is made and details on safety, immune response and whether it can prevent COVID-19 infection has left health experts and the public across the globe in dark,” he added. Dr Nisar said the rush to start using the vaccine before phase 3 trials, which normally lasts for months and involve thousands of people could backfire. “One of the biggest concerns about approving a new vaccine before clinical trials are complete is that it could jeopardize public trust in the vaccine development process and people may not use it,” he said. “Even the Moscow-based Association of Clinical Trials Organization, a trade body representing the world’s top drug makers in Russia had urged the Russian health ministry to postpone vaccine approval until the final trial is successfully completed. The World Health Organization has made it clear that any WHO stamp of approval on Russia’s COVID-19 vaccine would require a rigorous safety data review,” said Dr Nisar—(KNO) 

Trending

TOP STORIES ago

Dr Showkat Shah Expresses Gratitude to Mirwaiz Umar Farooq for Visiting His Father | KNO

TOP STORIES1 hours ago

Amit Shah to inaugurate 2-day 'Anti-Terror Conference' in New Delhi tomorrow | KNO

TOP STORIES1 hours ago

Three IAS officers shifted to J&K | KNO

TOP STORIES1 hours ago

Drug peddlers’ properties worth over Rs 100 crore attached in Srinagar: DC Labroo | KNO

TOP STORIES1 hours ago

Kulgam encounter: LeT commander Lateef Bhat killed after taking shelter inside mosque | KNO

TOP STORIES1 hours ago

Give us clarity on statehood restoration, don't humiliate us repeatedly, Omar to Centre | KNO

TOP STORIES1 hours ago

Dry spell may lower water levels across J&K | KNO

TOP STORIES1 hours ago

Shopian records coldest night in Kashmir at minus 3.6°C | KNO

TOP STORIES1 hours ago

FOOD SAFETY ROW: A day after CCIK warning, FDA seals Hattrick storage area in Rajbagh | KNO

TOP STORIES1 hours ago

Rotten meat trade: 7–8 FIRs registered, several arrested in Srinagar: SSP | KNO

TOP STORIES1 hours ago

For visually impaired Hafiz, security forces become ‘light’, rescue 25 girls from seminary in Kulgam | KNO

TOP STORIES1 hours ago

PG doctors’ stipend stir spreads across J&K; GMCs district hospitals to join agitation | KNO

TOP STORIES1 hours ago

Patient care hit as non-gazetted GMC employees continue protest | KNO

TOP STORIES1 hours ago

Daughter-in-law arrested in murder of 70-year-old Pulwama woman | KNO

TOP STORIES1 hours ago

Spl Secy Cabinet Secretariat reviews deregulation reforms with Chief Secretary Dr. Sajjan Singh Yadav | KNO

TOP STORIES2 hours ago

LeT’s last known active local terrorist killed in Kashmir: Amit Shah | KNO

TOP STORIES2 hours ago

Local terror recruitment near zero in J&K: DGP Prabhat | KNO

Copyright © 2021